BioChromatographix International (BCI) Officially Launches, Unveiling Next-Generation Monolithic Chromatography Media for the Future of Biotech Purification

Singapore, April 21, 2025 — BioChromatographix International (BCI), a pioneering biotech company developing breakthrough purification technologies, proudly announces its official public reveal. Headquartered in Singapore, BCI is redefining the standard for downstream processing with a new class of Next-Generation Monolithic Chromatography Media — purpose-built for the challenges of gene therapies, cell therapies, and advanced biologics manufacturing.

Founded by a team of scientists and entrepreneurs with a shared vision of smarter, faster, and more scalable purification, BCI’s mission is simple: Efficiency in Every Channel™. By combining novel methacrylic materials with proprietary monolithic architecture, BCI delivers unmatched flow performance and reliability — enabling drug developers and manufacturers to keep pace with the future of medicine.

“Chromatography has long been a cornerstone of bioprocessing, but many of today’s platforms are struggling to keep up with the scale, speed, and complexity required by modern biologics,” said Scott M. Wheelwright, PhD, Co-Founder & President of BCI. “We founded BCI to address those critical bottlenecks — by introducing Next-Generation Monolithic Chromatography Media that not only meets current needs but is built for the therapies of tomorrow. Our mission is to ensure that purification technologies evolve in step with innovation.”

“At BCI, we’re not just innovating in the lab — we’re building a platform for real-world impact,” said Chervee Ho, Co-Founder & Vice President of Commercial Operations. “From day one, our focus has been on scalability — both in terms of our technology and our reach. We’re developing solutions that are commercially viable, globally available, and ready to integrate into existing biomanufacturing workflows. It’s about giving biotech companies the tools they need to grow faster and go further.”

“Purification has long been one of the most complex and limiting steps in the development of advanced therapies,” said Prof. Alois Jungbauer, PhD, scientific advisor to BCI. “The innovation behind BCI’s monolithic media reflects a deep understanding of the real-world challenges in bioprocessing — particularly around flow dynamics, scalability, and emerging therapeutic modalities. What excites me most is the team’s commitment to turning bold ideas into practical solutions. I believe BCI’s approach will add meaningful value to the evolving landscape of gene and cell therapy manufacturing.”

BCI is proud to introduce its flagship platform, AXISFLOW™ — a portfolio of solid monolithic columns designed for the purification of AAV, lentivirus, plasmid DNA, mRNA, exosomes, virus-like particles and bacteriophage. Built with novel materials and flow-efficient architecture, AXISFLOW™ is developed to help scientists and manufacturers streamline their purification processes from bench to batch. As we take our first steps into the industry, we invite the biotech community to discover our technology, engage with us, and join us on this journey to bring next-generation purification to life.

As part of its public launch, BCI has unveiled a new corporate website and LinkedIn presence, inviting partners, investors, and collaborators to join its growing community of forward-thinking innovators.